Management of a 7 mm Raised Lesion in Barrett's Esophagus Suspicious for Dysplasia
The raised lesion must undergo endoscopic resection immediately to obtain definitive histologic diagnosis and provide therapeutic intervention. 1
Immediate Management: Endoscopic Resection
The presence of a visible raised lesion in Barrett's esophagus is an absolute indication for endoscopic resection, regardless of the degree of dysplasia suspected. 1 This approach serves dual purposes:
- Diagnostic: Provides complete histopathologic assessment of the lesion, including depth of invasion, differentiation grade, and presence of lymphovascular invasion 2
- Therapeutic: Removes the neoplastic tissue while preserving the esophagus 1
The AGA guideline explicitly states that any visible lesion in Barrett's esophagus should prompt endoscopic resection, and this should be performed before considering any ablation therapy. 1 The European Society of Gastrointestinal Endoscopy reinforces this, recommending endoscopic resection as curative treatment for T1a Barrett's cancer with well/moderate differentiation and no lymphovascular invasion. 2
Post-Resection Management Algorithm
After endoscopic resection, management depends entirely on the histopathologic findings:
If High-Grade Dysplasia or Intramucosal Adenocarcinoma (T1a):
- Complete ablation of all remaining Barrett's epithelium is mandatory 1, 2
- Ablation should extend 5-10 mm proximal to the squamocolumnar junction and 5-10 mm distal to the gastroesophageal junction 1
- This prevents progression from residual Barrett's tissue 2
If Low-Risk Submucosal Cancer (T1b sm1):
- Submucosal invasion ≤500 μm AND well/moderate differentiation AND no lymphovascular invasion qualifies as low-risk 2
- Endoscopic therapy with complete Barrett's eradication is reasonable, especially in poor surgical candidates 1
- Requires intensive follow-up with endoscopy, EUS, and CT/PET-CT in expert centers 2
If High-Risk Submucosal Cancer (T1b):
- Invasion >500 μm OR poor differentiation OR lymphovascular invasion present 2
- Requires multidisciplinary discussion for additional therapy (chemotherapy/radiotherapy/surgery) 2
Critical Procedural Requirements
This procedure must be performed in a high-volume expert center that performs a minimum of 10 new Barrett's endoscopic therapy cases annually. 1 This requirement exists because:
- Proper lesion characterization requires expertise in high-definition white-light endoscopy and chromoendoscopy 2
- Complete resection technique is technically demanding 3
- Accurate staging determines subsequent management 2
Common Pitfalls to Avoid
Never perform ablation therapy on a visible lesion without first resecting it. 1 Ablation destroys tissue architecture and prevents accurate histologic staging, which is essential for determining depth of invasion and risk stratification. 4
Do not proceed with ablation if inflammation is present in the Barrett's segment, as this increases complication risk and reduces efficacy. 1
Ensure complete pathologic review by an experienced pathologist to confirm the diagnosis and assess risk features, as this directly impacts subsequent management decisions. 2, 5
Adjunctive Medical Therapy
High-dose proton pump inhibitor therapy should be initiated during the treatment period to optimize healing and reduce inflammation. 6
Post-Treatment Surveillance
After successful endoscopic eradication of high-grade dysplasia or adenocarcinoma, surveillance endoscopy with biopsies should occur at 3,6, and 12 months, then annually thereafter. 1 The European guidelines recommend even more intensive surveillance at 1,2,3,4,5,7, and 10 years for baseline HGD/adenocarcinoma. 2